David Martin - Department of Pharmacology, Amgen

基本信息

浏览量：94

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 211 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Dose Escalation Study to Evaluate the Safety and Pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C Chemokine Receptor Type 5 Directed Antibody, in Patients with Systemic Lupus Erythematosus or Rheumatoid Arthritis

Stanley Cohen,Jean S. Beebe,Vishala Chindalore,Shunjie Guan,Mina Hassan-Zahraee, Madhurima Saxena,Li Xi,Craig Hyde, Sarita Koride,Robert Levin,Shannon Lubaczewski,Mikhail Salganik,Abigail Sloan,Erin Stevens,Elena Peeva,Michael S. Vincent,David A. Martin,Myron Chu

Arthritis Research & Therapy（2024）

引用0浏览0WOS引用

Efficacy and Safety of Tyrosine Kinase 2/Janus Kinase 1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial

Philip Mease,Philip Helliwell,Paula Silwinska-Stanczyk,Malgorzata Miakisz,Andrew Ostor,Elena Peeva,Michael S Vincent,Qiankun Sun,Vanja Sikirica,Randall Winnette,Ruolun Qiu, Gang Li, Gang Feng,Jean S Beebe,David A Martin

Arthritis & rheumatology (Hoboken, N.J.) (2023)

引用0浏览0WOS引用

A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a C-14-microdose approach

Ruolun Qiu,Raman Sharma, Hua Wei, Leonid Kirkovsky, Yifan Zhou,David D. A. Martin,Christopher Banfield,Martin E. Dowty

British journal of clinical pharmacologyno. 10 (2023): 3056-3066

引用0浏览0WOS引用

Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: an Open-Label, Phase 1 Study

David A. Martin,Jean-Baptiste Telliez,Susan Pleasic-Williams,Ying Zhang,Brendan Tierney,Matthew Blatnik,Jeremy D. Gale,Chris Banfield, Yifan Zhou,Alexandre Lejeune,Samuel H. Zwillich,Erin Stevens, Neeraj Tiwari,Elizabeth Kieras, Ashwin Karanam

Journal of clinical pharmacologyno. 1 (2023): 67-79

引用0浏览0WOS引用

Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial

Philip Mease,Philip Helliwell,Paula Silwinska-Stanczyk,Malgorzata Miakisz,Andrew Ostor,Elena Peeva,Michael S. Vincent,Qiankun Sun,Vanja Sikirica,Randall Winnette,Ruolun Qiu, Gang Li,Gang Feng,Jean S. Beebe,David A. Martin

ARTHRITIS & RHEUMATOLOGYno. 8 (2023): 1370-1380

引用2浏览0WOS引用

A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a ¹⁴C‐microdose approach

Ruolun Qiu,Raman Sharma, Hua Wei, Leonid Kirkovsky, Yifan Zhou,David Martin,Christopher Banfield,Martin E. Dowty

British Journal of Clinical Pharmacologyno. 10 (2023): 3056-3066

引用0浏览0引用

After 25 years of drug development, do we know JAK

Mahta Mortezavi,David A. Martin,Hendrik Schulze-Koops

RMD OPEN（2022）

引用4浏览0WOS引用

The Management of Obesity

Wendy A. Brown,David Martin

Clinical Obesity in Adults and Childrenpp.297-305, (2022)

引用0浏览0引用

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors

Jeffrey Weitz,Zoltan Szekanecz,Christina Charles-Schoeman,Ivana Vranic, Burak Sahin,Sara A. Paciga, Zhenyu Wang,Craig Hyde,David A. Martin

RMD Open（2022）

引用1浏览0WOS引用

Critical Evaluation of Specific Efficacy of Potentised Preparations in a Plant-Based Bioassay

Annekathrin Ücker,Stephan Baumgartner,David Martin,Tim Jäger

European journal of integrative medicine（2021）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn